Zhengzhou, China – April 10, 2015, Zhengzhou Granlen PharmaTech Ltd, aDivision of Granlen, Inc. in San Diego, California, USA, will present the newlydiscovered and developed fluoro-nucleosidesatTIDES 2015, and exhibits as a sponsor. The novelnucleosides will be released for the first time, and can be utilized for smallmolecule drug discovery, genomic therapy, and biologics.

“We arepleased to release novel nucleosides and extend our list of nucleosides and related derivativesin hoping topromote the discovery and development of more genomic and related drugs.” SaidHarry An, Ph. D., Founder and President, Granlen.

For moreinformation on Granlen’sintroduction, pleasevisit the company’s website at www.granlen.com or send inquiry to info@granlen.com, or contact:

Ms. Sherry Li, sherry.li@granlen.com; +86-371-86026726

Dr. HarryAn, han@granlen.com.

ZhengzhouGranlen PharmaTech Ltd., a Division of Granlen